Posted by Michael Wonder on 21 Jun 2024
Johnson & Johnson submits application to US FDA seeking approval of Tremfya (guselkumab) for the treatment of moderately to severely active Crohn's disease
20 June 2024 - Submission is supported by 48 week results from the Phase 3 GALAXI and GRAVITI programs.
Johnson & Johnson today announced the submission of a supplemental biologics license application to the US FDA seeking approval of Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease.
